{"id":"NCT01628393","sponsor":"Celgene","briefTitle":"Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients","officialTitle":"A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2012-09-18","primaryCompletion":"2014-04-13","completion":"2016-05-11","firstPosted":"2012-06-26","resultsPosted":"2021-02-11","lastUpdate":"2021-02-11"},"enrollment":258,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Relapsing Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"Ozanimod","otherNames":["RPC1063","ZeposiaÂ®"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Ozanimod 0.5 mg","type":"EXPERIMENTAL"},{"label":"Ozanimod 1 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study is a two-part trial consisting of Part A (presented in this record) and Part B (see NCT02047734).\n\nThe primary objective in Part A of this study was to demonstrate the superior efficacy of ozanimod compared to placebo by showing a reduction in the cumulative number of total gadolinium-enhancing (GdE) lesions from Week 12 to Week 24 in patients with relapsing multiple sclerosis (RMS).","primaryOutcome":{"measure":"Total Number of Gadolinium-Enhancing (GdE) Lesions Assessed on Brain Magnetic Resonance Imaging (MRI) From Week 12 to Week 24","timeFrame":"From Week 12 to Week 24; MRI was performed at Weeks 12, 16, 20, and 24","effectByArm":[{"arm":"Placebo","deltaMin":11.1,"sd":29.87},{"arm":"Ozanimod 0.5 mg","deltaMin":1.9,"sd":4.77},{"arm":"Ozanimod 1 mg","deltaMin":1.5,"sd":3.44}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":1},"locations":{"siteCount":58,"countries":["United States","Belgium","Bulgaria","Georgia","Greece","Hungary","Italy","Poland","Romania","Russia","Serbia","Spain","Ukraine"]},"refs":{"pmids":["26879276","30043658"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":88},"commonTop":["Nasopharyngitis","Upper Respiratory Tract Infection","Headache","Alanine Aminotransferase Increased","Back Pain"]}}